Скачать или смотреть Psychedelic Biotech in 2025: What's Next? | Florian Brand and Lars Wilde

Jake speaks with Florian Brand and Lars Wilde, Co-Founders of atai Life Sciences (now AtaiBeckley) and Compass Pathways. In this conversation, we discuss their backgrounds, what led them into psychedelic drug development, and what inspired them to start two of the most influential companies in the space.

We cover the major developments of the past year, including AbbVie’s up to $1.2 billion acquisition of Bretisilocin, what we know about the compound, the type of psychedelic experience it produces, and why the deal terms were so significant. Florian and Lars share their views on what this deal means for future M&A activity, potential licensing opportunities, and whether multiple short, medium, and long-duration psychedelics can succeed commercially.

We also talk about efficacy in MDD versus TRD, opportunities for psychedelics beyond depression such as substance use disorders, TBI, and pain, and the data needed to expand into new indications. Florian and Lars close by sharing what they are most looking forward to in the coming months and years in psychedelic medicine.

Link to Florian and Lars' Substack: https://brandflorian.substack.com/

Disclaimer: The content presented on this YouTube channel is for informational and entertainment purposes only. The opinions expressed are solely those of the content creators and should not be construed as financial, investment, or professional advice. Viewers are advised to conduct their own research, consider their individual financial circumstances, and consult with a qualified professional before making any investment decisions.

#PsychedelicInvesting #PsychedelicResearch #PsychedelicStocks #Psilocybin #DMT #Pharma #AbbVie